Emerald gleams for Morphic
Ulcerative colitis data promise the efficacy and safety of Entyvio, but in a pill.
Takeda taps Innate for a new coeliac approach
The Japanese developer is an active name in the autoimmune condition, and with its first deal over ADCs it joins others with antibody approaches.
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
Lilly and Pfizer fight for new territory in obesity and diabetes
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.